Clinical and Pathologic Response to Therapy in Gastrointestinal Oncology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 16668
Special Issue Editors
Interests: cholangiocarcinoma (bile duct cancer); colon cancer; colorectal cancer; gallbladder cancer; liver cancer; neuroendocrine tumor; rectal cancer; small intestine cancer
Special Issue Information
Dear Colleagues,
With a growing focus on multimodality therapy for a variety of gastrointestinal cancers, there has been a movement to emphasize therapies in the neoadjuvant setting. One major potential advantage of this approach is the ability to study treatment effects of therapies for tumors in their original location. However, with an ever-expanding array of novel treatments, including, but not limited to, immune and targeted therapies, the study of treatment response becomes increasingly complex. Research efforts are needed to improve our understanding of tumor response biology and the subsequent prognostic and therapeutic implications. This Special Issue focuses on recent efforts (original research and reviews) to study tumor responses to oncologic therapy across gastrointestinal oncology.
Dr. Daniel A. Anaya
Dr. Andrew J. Sinnamon
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor regression
- treatment response
- clinical response
- pathologic response
- neoadjuvant therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.